Litchfield Hills analyst Theodore O’Neill initiated coverage of Inspira Technologies (IINN) with a Buy rating and $2 price target Inspira is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, the analyst tells investors in a research note. The firm says the company has a “well-protected technology moat” that includes both patented technology and technical trade secrets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance
- Inspira Technologies Launches Global Rollout of ART100 System
- Inspira initiates global commercial rollout of ART100 system
- Inspira Technologies Restructures Executive Team for Strategic Alignment
- Inspira Technologies president Joe Hayon steps down